Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel inhibitor compounds of phosphodiesterase type 10a

a technology of phosphodiesterase and inhibitor compounds, which is applied in the direction of biocide, drug compositions, metabolic disorders, etc., can solve the problems of short exposure half-life after systemic administration, poor potency and selectivity of papaverine, and significant limitations in this regard, and achieve enhanced metabolic stability, high selectivity, and high selectivity

Inactive Publication Date: 2013-05-09
ABBVIE INC +1
View PDF0 Cites 26 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about new compounds that can treat medical disorders such as neurological and psychiatric disorders by inhibiting an enzyme called phosphodiesterase type 10A. These compounds can be used to make a medication and reduce symptoms associated with these disorders. The technical effect of this patent is the discovery of new tools to help develop treatments for medical disorders.

Problems solved by technology

Papaverine, however has significant limitations in this regard with relatively poor potency and selectivity and a very short exposure half-life after systemic administration.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel inhibitor compounds of phosphodiesterase type 10a
  • Novel inhibitor compounds of phosphodiesterase type 10a
  • Novel inhibitor compounds of phosphodiesterase type 10a

Examples

Experimental program
Comparison scheme
Effect test

preparation examples

I. Preparation of Intermediates

[0957]The starting materials used in the examples are either commercially available or can be synthesized by the average skilled person trained in organic chemistry following routine laboratory practice as outlined, for example in the examples below.

a) Preparation of Compounds of the General Formula Het-A′-OH

a1) 2-Quinolin-2-yl-ethanol

[0958]

a1.1) Quinolin-2-yl-acetic acid ethyl ester

[0959]To a suspension of vacuum dried Zn dust (6.0 g, 93.8 mmol) in dry THF (100 mL) was added TMSCl (0.5 mL) dropwise over 5 min under N2 atmosphere and under stiffing. The mixture was stirred for 30 min and warmed to 45° C. Ethyl bromoacetate (5.2 mL, 46.9 mmol) was added dropwise via a syringe. After addition, the mixture was stirred at the same temperature for 1 h. After sedation at room temperature for 2 h, a clear orange solution was formed. The orange solution (50 mL) was carefully sucked into a syringe through a long needle and added to a mixture of 2-bromoquinoline...

example 1

3,7-Di(pyridin-4-yl)-5-[2-(quinolin-2-yl)ethyl]thieno[2,3-d]pyridazin-4(5H)-one

[1029]

1.1 4-Bromothiophene-3-carboxylic acid

[1030]To a mixture of Mg (1.4 g, 60 mmol) and I2 (0.1 g) in anhydrous THF (2 mL) was added dropwise a solution of 2-bromo-propane (7.4 g, 60 mmol) in anhydrous THF (60 mL) at room temperature under nitrogen during a period of 30 min After the addition, the mixture was refluxed until the most of magnesium was consumed. The resulting Grignard reagent was added dropwise to a solution of 3,4-dibromo-thiophene (12.1 g, 50 mmol) in anhydrous THF (60 mL) at 0° C. under nitrogen within about 30 min. The mixture was allowed to stir at 0° C. for 1.5 h. Excessive CO2 was purged into the mixture at −30° C. and the reaction mixture was stirred until the temperature rose to room temperature. Then the reaction was quenched with water (30 mL) and basified with 8% aq. NaOH solution to pH 11 and was washed with ethyl acetate (3×60 mL). The aqueous layer was acidified with 5% aq. ...

example 2

7-(Pyridin-4-yl)-5-[2-(quinolin-2-yl)ethyl]thieno[2,3-d]pyridazin-4(5H)-one

[1041]

2.1 2-Isonicotinoylthiophene-3-carboxylic acid

[1042]To a solution of diisopropylamine (5.2 g, 51.5 mmol) in anhydrous THF (40 mL) at −30° C. was added n-BuLi (23.2 mL, 56.2 mmol, 2.5M in THF) dropwise. The mixture was stirred at the same temperature for 0.5 h, then cooled to −78° C. and HMPA (0.8 g, 4.7 mmol) was added slowly. Then a solution of thiophene-3-carboxylic acid (3.0 g, 23.4 mmol) in anhydrous THF (50 mL) was added slowly. The mixture was stirred at the same temperature for 1 h, N-methoxy-N-methyl-4-pyridinecarboxamide (5.0 g, 46.9 mmol) was added drop wise into the stirring mixture at −78° C. The reaction mixture was stirred for another 1 h at room temperature and was then quenched with H2O (10 mL). The aqueous layer was acidified with 5% aq. HCl to pH 1˜2, the precipitate was collected by filtration. The filter cake wash with DCM and the filtrate was extracted with DCM (3×200 mL). The organ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
enantiomeric excessaaaaaaaaaa
chemicalaaaaaaaaaa
chemical bondaaaaaaaaaa
Login to View More

Abstract

The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.whereinQ is O or S, X1 is N or CH, X2 is N or C—R7; X3 is O, S—X4═C(R8)—, where C(R8) is bound to the carbon atom which carries R2, or —X5═C(R9)—, where X5 is bound to the carbon atom which carries R2; X4 is N or C—R9; X5 is N;Het is selected from optionally substituted phenyl, monocyclic hetaryl and fused bicyclic hetaryl;R1 is selected inter alia from hydrogen, halogen, OH, C1-C4-alkyl, trimethylsilyl, C1-C4-alkylsulfanyl, C1-C4-alkoxy-C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkoxy, the moiety Y1-Cyc1;R2 is selected inter alia from hydrogen, halogen, OH, C1-C4-alkyl, trimethylsilyl, C1-C4-alkoxy-C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkoxy, C2-C4-alkenyloxy, etc;A represents one of the following groups A1, A2, A3, A4 or A5:where * indicates the points of attachment to Het and to the nitrogen atom, respectively;and where R3 to R9, R3e, R3f, A′, Y1 and Cyc1 are defined in the claims.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This claims priority to U.S. Provisional Patent Application No. 61 / 557,874, filed on Nov. 9, 2011, the contents of which are herein fully incorporated by reference.[0002]The present invention relates to novel compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.BACKGROUND OF THE INVENTION[0003]Phosphodiesterase type 10A (hereinafter PDE10A) is a dual-substrate phosphodiesterase that can convert both cAMP to AMP and cGMP to GMP. PDE10A is highly prominent in the mammalian brain. In the rat, as well as in other mammalian species, PDE10A and the mRNA of PDE10A are highly enriched in the GABAergic medium spiny projection neurons (MSNs) of the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D495/04C07D471/04C07D417/14
CPCC07D519/00C07D495/04C07D401/14C07D413/14C07D471/04C07D417/14C07D491/048C07D401/06C07D401/08C07D405/14A61P25/00A61P25/04A61P25/14A61P25/18A61P25/22A61P25/24A61P25/28A61P3/04A61P43/00
Inventor GENESTE, HERVÉOCHSE, MICHAELDRESCHER, KARLATURNER, SEANBEHL, BERTHOLDLAPLANCHE, LOICDINGES, JÜRGENJAKOB, CLARISSABLACK, LAWRENCE
Owner ABBVIE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com